Vein transplantation of human umbilical cord blood mesenchymal stem cells improves neurological function recovery after spinal cord injury in rats
HT Zhang,HL Yang,J Qu,J Zhang,B Meng,ZG Zhang,TS Tang,YZ Xu,WM Jiang
DOI: https://doi.org/10.3321/j.issn:1673-8225.2007.15.028
2007-01-01
Abstract:Aim: To observe the vein translated human umbilical cord blood (hUCB) mesenchymal stem cells infiltrating into the injured spinal cord tissues by Brdu immunohistochemical labeled technique and explore its role of improving neurological function recovery. Methods: The experiment was performed in Stem Cell Laboratory of the Biotechnology Institute of Soochow University from October 2003 to March 2005. 1 Totally 60 healthy adult Wistar rats were selected randomly into sham operation group, model control group and stem cell transplantation group with 20 in each group. Cord blood preparation was provided by Department of Maternity, First Affiliated Hospital, Soochow University. Parturients and their family members signed the informed consent. 2 50-60 mL fresh cord blood was obtained from cord blood. hUCB mesenchymal stem cells were isolated and cultured. Cells were adjusted to 5×109 L-1, which were marked by Brdu 48 hours before transplantation. 3 Spinal cord injury models were established by compression method in rats of model control group and stem cell transplantation group. Rats were anesthetized at prone position and cut at middle back, striped paravertebral muscles, get rid of T11 spinal process and vertebral plate to expose 4 mm×5 mm spinal dura mater. 55 g counterweight was put on spinal dura mater for 1 minute, and then the wound was directly sewn. Only spinal dura mater was exposed in the sham operation group, and then the wound was sewn. 4 5 days after establishing models, 0.2 mL-0.3 mL hUCB mesenchymal stem cells suspension (total 1×106) were slowly injected in great saphenous vein of the hind limb in the stem cell transplantation group. Those in the model control group and sham operation group received saline of the same volume. 5 1 day, 1, 2, 3 weeks after cell transplantation, neurological function was assessed respectively by Basso Beatlie Bresnahan (BBB) and inclined plane test. 1 and 3 weeks after cell transplantation, frozen section was made to test the distribution of hUCB mesenchymal stem cells in spinal cord tissue in each group. Results: 1 neurological function determination: Within 3 weeks after spinal injury cell transplantation, the motor function of the hind limb in the model control group and the stem cell transplantation group was recovered, but the recovery was rapid in the stem cell transplantation group. The recovery determined by BBB score and inclined plane test was significantly improved as compared with the model control group [(10.71±6.24), (5.13±3.36) points, t =2.39, P < 0.05; (51.67±5.22), (46.63±3.72)°, t =3.39, P < 0.01], and maintained till the 3rd week after operation [(17.29±4:O3), (11.25±5.01) points, t =3.89, P < 0.01; (65.77±8.06), (57.05±4.61)°, t =4.07, P < 0.01]. 2 identification of hUCB mesenchymal stem cells in spinal cord tissue: There was no positive Brdu expression in the spinal cord tissue in sham operation group and model control group. A mass of positive brown Brdu expression hUCB mesenchymal stem cells appeared in injured spinal cord 1 week after transplantation in the stem cell transplantation group, and maintained till the 3rd week after transplantation while no Brdu positive cells could be seen in the other two groups. Conclusion: Brdu has a good labeled effect on hUCB mesenchymal stem cells. Via vein administered hUCB mesenchymal stem cells can infiltrate into the spinal cord injury region and improve neurological function.